Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease

• US 6,255,296 B1
• Filed: 04/30/1999
• Issued: 07/03/2001
• Est. Priority Date: 01/11/1994
• Status: Expired due to Fees

• Current Assignee: Bruce A. Daniels, Endomatrix, Inc.
• Original Assignee: Endomatrix, Inc.
• Inventors: Daniels, Bruce A.
• Primary Examiner(s): PADMANABHAN, SREENIVASAN
• Application Number:
  US09/302,690
• Time in Patent Office: 795 Days
• Field of Search: 514/56, 514/561, 514/564, 514/822, 514/824
• US Class Current: 514/56
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/34 having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
• CPC Class Codes: A61K 31/557 Eicosanoids, e.g. leukotrienes or prostaglandins
• CPC Class Codes: A61K 31/727 Heparin; Heparan
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A method for inhibiting the effects of cardiovascular disorders and diseases in a host susceptible to or suffering from a cardiovascular disorder or disease comprising administering to the host, a therapeutically effective amount of a first substance characterized as simulating a heparin-like effect, and a therapeutically effective amount of a second substance characterized as simulating an arginine-like effect; and a formulation for use in treating a host susceptible to or suffering from the effects of cardiovascular disorders and diseases comprising a therapeutically effective amount of a first substance characterized as simulating a heparin-like effect, and a second substance characterized an simulating an arginine-like effect, an described.

Claims

1. A method for treating a patient susceptible to or suffering from at least one of atherosclerosis, arteriosclerosis, congestive heart failure, stroke, arterial dysfunction, re-stenosis, hypertension, smooth muscle cell hydrophy, thrombogenicity, clotting disorders, platelet disorders, myocardial infarction, cerebrovascular ischemia, or peripheral vascular ischemia, said method comprising orally administering to said patient a therapeutically effective amount of a first substance selected from the group consisting of heparin, heparin sulfate, taprostene, prostacyclin, and physiologically acceptable salts thereof, and a therapeutically effective amount of a second substance selected from the group consisting of arginine, arginine sulfate, and physiologically acceptable salts thereof.

2. The method of claim 1 wherein said first substance is exogenous heparin.

3. The method of claim 1 wherein said first substance is dispersed in a physiologically acceptable carrier.

4. The method of claim 3 wherein said physiologically acceptable carrier is water.

5. The method of claim 1 wherein said first substance is administered subcutaneously, intravenously, rectally, transdermal or intra pulmonary.

6. The method of claim 1 wherein said second substance is arginine, a functional analog of arginine, a physiological acceptable salt of arginine, or a physiologically acceptable salt of a functional analog of arginine.

7. The method of claim 6 wherein said second substrate is exogenous L-arginine.

8. The method of claim 1 wherein said second substance is dispersed in a physiologically acceptable carrier.

9. The method of claim 8 wherein said physiologically acceptable carrier is water.

10. The method of claim 1 wherein said second substance is administered subcutaneously, intravenously, rectally, transdermally or intra pulmonary.

11. The method of claim 1 wherein said first substance and said second substance are co-administered orally.

12. The method of claim 1 wherein said therapeutically effective amount of the first substance is characterized as containing about 2000 to 200,000 units of heparin, heparin sulfate, taprostene, prostacyclin, or a physiologically acceptable salt thereof.

13. The method of claim 1 wherein said therapeutically effective amount of the second substance comprises about 500 to 50,000 mg arginine, arginine sulfate, or a physiologically acceptable salt thereof.

14. A method of treating cardiovascular disease comprising the step of administering a mixture of arginine and heparin in therapeutic proportions.

15. The method of claim 14, for the treatment of angina pectoris.

16. The method of claim 14, for treatment of cardiovascular systems.

17. The method of claim 14, for oral administration.